Lincoln Pharmaceuticals (NSE:LINCOLN) disclosed its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, at a board meeting held on August 13, 2026. Standalone net profit for Q1 FY27 stood at Rs 3,623.45 lakh, up 30.9% from Rs 2,767.52 lakh in Q1 FY26.
Key Highlights
- Standalone revenue from operations for Q1 FY27 rose to Rs 17,728.21 lakh, compared with Rs 15,406.67 lakh in Q1 FY26, reflecting a year-on-year increase of approximately 14.9%.
- Standalone profit before tax reached Rs 4,755.38 lakh in Q1 FY27, up from Rs 3,538.92 lakh in the same quarter of the previous year.
- Basic and diluted earnings per share on a standalone basis stood at Rs 18.09 for Q1 FY27, against Rs 13.82 for Q1 FY26, on a face value of Rs 10 per share.
- Consolidated figures are identical to standalone figures for Q1 FY27, with no non-controlling interest reported, indicating the group operates as a single economic entity for this period.
About the Company
Lincoln Pharmaceuticals Limited, headquartered at "Lincoln House," Science City Road, Sola, Ahmedabad, Gujarat, manufactures and markets a range of pharmaceutical formulations including tablets, capsules, dry syrups, and injectables. The company operates a manufacturing facility at Khatraj, Gandhinagar district, Gujarat, and is listed on NSE under the ticker LINCOLN with CIN L24230GJ1995PLC024288. It operates in a single business segment: the Pharmaceutical Business.
Announcement in Detail
The board of directors met on August 13, 2026, and approved the unaudited standalone and consolidated financial results for Q1 FY27 under Regulation 33 of the SEBI Listing Regulations. The audit committee reviewed and recommended the results before board approval, and auditors Samir M. Shah and Associates issued a limited review report with no material misstatements noted.
On a standalone basis, total income for Q1 FY27 was Rs 20,154.67 lakh, against Rs 16,933.84 lakh in Q1 FY26. Total expenses were Rs 15,399.29 lakh for the quarter, compared with Rs 13,394.92 lakh a year earlier. The paid-up equity share capital remained unchanged at Rs 2,002.97 lakh, with other equity of Rs 73,760.23 lakh as at the reporting date.
Impact on Investors
Investors will note that the year-on-year improvement in standalone net profit, from Rs 2,767.52 lakh to Rs 3,623.45 lakh, was accompanied by a meaningful sequential recovery as well: the preceding quarter ended March 31, 2026 reported a standalone net profit of only Rs 1,163.46 lakh. The filing shows total comprehensive income on a standalone basis reached Rs 3,665.33 lakh in Q1 FY27, compared with Rs 2,769.81 lakh in Q1 FY26.
Shareholders will observe that the deferred tax charge of Rs 596.63 lakh in Q1 FY27 is materially higher than Rs 359.10 lakh in Q1 FY26, which contributed to the effective tax rate being elevated relative to the pre-tax profit expansion. The results have been prepared under Ind AS and carry a limited review, not a full audit, which is standard practice for interim quarterly disclosures under SEBI regulations.
Sector / Market Context
India's pharmaceutical industry remains one of the country's largest export contributors, with the sector supplying formulations to regulated markets including the United States, Europe, and Africa. According to data cited by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), Indian pharma exports have consistently grown over recent years. Domestic formulation consumption has also expanded, supported by government healthcare programmes such as the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, which broadens the addressable market for mid-sized manufacturers like Lincoln Pharmaceuticals.